Systematic Scoring Balloon Lesion Preparation for Drug-Coated Balloon Angioplasty in Clinical Routine: Results of the PASSWORD Observational Study.
Klaus Bonaventura,Markus Schwefer,Ahmad Khairuddin Mohamed Yusof,Matthias Waliszewski,Matthias Waliszewski,Florian Krackhardt,Philip Steen,Raymundo Ocaranza,Ahmad Syadi Mahmood Zuhdi,Liew Houng Bang,Kristof Graf,Ulrich Böck,Kenneth Chin +12 more
Reads0
Chats0
TLDR
The routine use of a non-slip element scoring balloon catheter to prepare lesions suitable for drug-coated balloon angioplasty is associated with high procedural success rates and low TLF rates in de novo lesions.Abstract:
Scoring balloon angioplasty (SBA) for lumen gain prior to stent implantations or drug-coated balloon angioplasty (DCB) is considered an essential interventional tool for lesion preparation. Recent evidence indicates that SBA may play a pivotal role in enhancing the angiographic and clinical outcomes of DCB angioplasty. We studied the systematic use of SBA with a low profile, non-slip element device prior to DCB angioplasty in an unselected, non-randomized patient population. This prospective, all-comers study enrolled patients with de novo lesions as well as in-stent restenotic lesions in bare metal stents (BMS-ISR) and drug-eluting stents (DES-ISR). The primary endpoint was the target lesion failure (TLF) rate at 9 months (ClinicalTrials.gov Identifier NCT02554292). A total of 481 patients (496 lesions) were recruited to treat de novo lesions (78.4%, 377), BMS-ISR (4.0%, 19), and DES-ISR (17.6%, 85). Overall risk factors were acute coronary syndrome (ACS, 20.6%, 99), diabetes mellitus (46.8%, 225), and atrial fibrillation (8.5%, 41). Average lesion lengths were 16.7 ± 10.4 mm in the de novo group, and 20.1 ± 8.9 mm (BMS-ISR) and 16.2 ± 9.8 mm (DES-ISR) in the ISR groups. Scoring balloon diameters were 2.43 ± 0.41 mm (de novo), 2.71 ± 0.31 mm (BMS-ISR), and 2.92 ± 0.42 mm (DES-ISR) whereas DCB diameters were 2.60 ± 0.39 mm (de novo), 3.00 ± 0.35 mm (BMS-ISR), and 3.10 ± 0.43 mm (DES-ISR), respectively. The overall accumulated TLF rate of 3.0% (14/463) was driven by significantly higher target lesion revascularization rates in the BMS-ISR (5.3%, 1/19) and the DES-ISR group (6.0%, 5/84). In de novo lesions, the TLF rate was 1.1% (4/360) without differences between calcified and non-calcified lesions (p = 0.158) and small vs. large reference vessel diameters with a cutoff value of 3.0 mm (p = 0.901). The routine use of a non-slip element scoring balloon catheter to prepare lesions suitable for drug-coated balloon angioplasty is associated with high procedural success rates and low TLF rates in de novo lesions.read more
Citations
More filters
Journal ArticleDOI
Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies
TL;DR: A very brief summary about the effective therapeutic methods cooperating specifical targets and positioning-delivery strategies in atherosclerosis for better outcomes is achieved.
Journal ArticleDOI
Choosing the right treatment for the right lesion, Part II: a narrative review of drug-coated balloon angioplasty and its evolving role in dialysis access maintenance
TL;DR: A comprehensive overview of drug-coated balloon (DCB) mechanisms, implementation, and design is provided in this paper , followed by an examination of the evidence basis for their use in arteriovenous access stenosis.
Journal ArticleDOI
Shockwave coronary intravascular lithotripsy system for heavily calcified de novo lesions and the need for a cost-effectiveness analysis
TL;DR: In this paper , the authors proposed a novel option for lesion preparation of heavily calcified plaques in coronary and peripheral vessels based on the fundamental principles of lithotripsy, a technology that has been used to modify renal stones for over 30 years.
Journal ArticleDOI
The factors influencing the efficiency of drug-coated balloons
TL;DR: This review is the first to summarize the key influencing factors of DCB efficiency in terms of balloon structure and principles, and then it analyzes how these factors cause outcomes in practice based on current clinical trial studies of DCBs in the treatment of different types of lesions.
Journal ArticleDOI
Shockwave coronary intravascular lithotripsy system for heavily calcified de novo lesions and the need for a cost-effectiveness analysis
George Kassimis,Antonios Ziakas,Matthaios Didagelos,Konstantinos Theodoropoulos,Dimitrios Patoulias,Petros Voultsos,Christodoulos Papadopoulos,Paul Rocchiccioli,Grigoris V Karamasis,Dimitrios Alexopoulos,George Sianos +10 more
TL;DR: In this paper, the authors proposed a novel option for lesion preparation of heavily calcified plaques in coronary and peripheral vessels based on the fundamental principles of lithotripsy, a technology that has been used to modify renal stones for over 30 years.
References
More filters
Journal ArticleDOI
Third universal definition of myocardial infarction
Kristian Thygesen,Joseph S. Alpert,Allan S. Jaffe,Maarten L. Simoons,Bernard R. Chaitman,Harvey D. White +5 more
TL;DR: Information on MI rates can provide useful information regarding the burden of CAD within and across populations, especially if standardized data are collected in a manner that …
Journal ArticleDOI
2018 ESC/EACTS Guidelines on myocardial revascularization.
Miguel Sousa-Uva,Franz-Josef Neumann,Anders Ahlsson,Fernando Alfonso,Adrian P. Banning,Umberto Benedetto,Robert A. Byrne,Jean-Philippe Collet,Falk,Stuart J. Head,Peter Jüni,Adnan Kastrati,Akos Koller,Steen Dalby Kristensen,Josef Niebauer,Dimitrios J. Richter,Petar M. Seferovic,Dirk Sibbing,Giulio G. Stefanini,Stephan Windecker,Rashmi Yadav,Michael O. Zembala +21 more
TL;DR: Authors/Task Force Members: Franz-Josef Neumann* (ESC Chairperson) (Germany), Miguel Sousa-Uva* (EACTS Chair person) (Portugal), Anders Ahlsson (Sweden), Fernando Alfonso (Spain), Adrian P. Banning (UK), Umberto Benedetto (UK).
Journal ArticleDOI
Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome.
Masakazu Yamagishi,Mitsuyasu Terashima,Kojiro Awano,Mikihiro Kijima,Satoshi Nakatani,Satoshi Daikoku,Kenichi Ito,Yoshio Yasumura,Kunio Miyatake +8 more
TL;DR: Large eccentric plaque containing an echolucent zone by IVUS can be at increased risk for instability even though the lumen area is preserved at the time of initial study.
Journal ArticleDOI
Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document
Hector M. Garcia-Garcia,Eugene P. McFadden,Andrew Farb,Roxana Mehran,Gregg W. Stone,John A. Spertus,Yoshinobu Onuma,Marie-Angèle Morel,Gerrit-Anne van Es,Bram D. Zuckerman,William F. Fearon,David P. Taggart,Arie-Pieter Kappetein,Mitchell W. Krucoff,Pascal Vranckx,Stephan Windecker,Donald E. Cutlip,Donald E. Cutlip,Patrick W. Serruys +18 more
TL;DR: This Academic Research Consortium-2 document provides further standardization of end point definitions for coronary device trials, incorporating advances in technology and knowledge that will aid interpretation of trial outcomes and comparison among studies, thus facilitating the evaluation of the safety and effectiveness of these devices.
Journal ArticleDOI
A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study.
Azeem Latib,Antonio Colombo,Fausto Castriota,Antonio Micari,Alberto Cremonesi,Francesco De Felice,Alfredo Marchese,Maurizio Tespili,Patrizia Presbitero,Gregory A. Sgueglia,Francesca Buffoli,Corrado Tamburino,Ferdinando Varbella,Alberto Menozzi +13 more
TL;DR: Treatment of small-vessel disease with a paclitaxel DEB was associated with less angiographic late loss and similar rates of restenosis and revascularization as a PES.